PRODUCTS

DNAnexus Apollo

The interactive discovery platform connecting omics results with phenotypic data to drive translational research.

Apollo-header
  • EpicCypher
  • dana-farber
  • biobank
  • natera
  • regeneron
  • lily
  • biomarin
  • merck
  • our-future-health
  • nhs
  • gsk
  • emory-winship
  • ucla
  • chdi
  • st-jude
  • myriad-genetics
  • challenge-works
  • carigenetics
  • novartis
  • city-of-hope

Unify omics results with clinical data
to power precision medicine.

DNAnexus Apollo™ is the interactive clinico-genomic discovery platform built to accelerate biomarker identification, patient stratification, and translational research. It transforms static bioinformatics results into annotated, query-ready data, linking germline, somatic, and expression data with clinical and phenotypic records. Through a Cohort Browser and programmatic access, Apollo gives biopharma, diagnostic providers, and health systems a faster path from data to tested hypotheses.

Omics results from clinical trials, biobanks, and licensed real-world data often remain locked in static bioinformatics files that require custom scripting to interrogate.

Apollo ingests these complex datasets into a standardized, query-ready asset where translational and clinical scientists can assess trial feasibility, locate sub-cohorts for follow-up studies, compare cohorts to test hypotheses, and explore potential biomarkers themselves.

Teams get answers sooner, and bioinformaticians regain time for higher-value work.

Global biopharma leaders rely on Apollo to maximize the value of their omics data.

Health systems generate NGS results from in-house panel testing, external send-out diagnostics, and research sequencing, often in disconnected streams.

Apollo brings these sources together with electronic health record and outcome data in one queryable dataset, so researchers and clinicians across the institution can safely interrogate patient populations for translational research and population health initiatives.

Leading cancer centers leverage Apollo to bridge routine clinical testing and discovery science ensuring the patient data is protected every step of the way.

Testing providers hold years of molecular results with significant research and commercial value, but showing prospective partners what that data contains without releasing sensitive records is difficult.

Apollo turns aggregated test results into an interactive showcase where partners can evaluate cohort sizes by molecular alteration, disease stage, and clinical characteristics.

Collaborators confirm the data fits their exact criteria before proceeding with licensing, eliminating weeks of manual feasibility queries.

DNAnexus Apollo Capabilities

  • Multi-Omics Data Model
  • Integrated Variant Annotation
  • Flexible Clinical Data Integration
  • No-Code Cohort Building
  • Interactive Visualizations
  • SQL and Programmatic Querying
  • Scalable Data Science
  • Inherited DNAnexus Titan Capabilities
  • Omics Data Agent Integration
“The best thing you can do with DNAnexus is give them a problem to solve.”
Jeffrey Reid, VP, Chief Data Officer | Regeneron Genetics Center
“Security is super important to us and the DNAnexus platform has an absolutely fantastic security model underneath.”
Mahesh Pancholi, Chief Information Officer | UK Biobank
"DNAnexus has made it easy for us to remove the costs and technical headaches associated with building a do-it-yourself alternative."
Jonathan Sheena, Co-Founder and CTO | Natera

Fresh Perspectives